ADCT

ADC Therapeutics SA

Add to Watchlist

Advanced Chart

2.940

+0.05(1.730%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.070

Open

2.960

VWAP

2.99

Vol

1.16M

Mkt Cap

291.58M

Low

2.890

Amount

3.47M

EV/EBITDA(TTM)

Total Shares

96.23M

532.54M

EV/OCF(TTM)

P/S(TTM)

3.94

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

18.46M

+9.14%

18.32M

-0.78%

17.86M

+2.59%

Estimates Revision

The market is revising Upward the revenue expectations for ADC Therapeutics SA (ADCT) for FY2025, with the revenue forecasts being adjusted by 4.17% over the past three months. During the same period, the stock price has changed by 105.59%.

Revenue Estimates for FY2025

Revise Upward

+4.17%

In Past 3 Month

Stock Price

Go Up

+105.59%

In Past 3 Month

2 Analyst Rating

155.10% Upside

Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.50 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

155.10% Upside

Current: 2.940

Low

5.00

Averages

7.50

High

10.00

155.10% Upside

Current: 2.940

Low

5.00

Averages

7.50

High

10.00

RBC Capital

Gregory Renza

Outperform

downgrade

$8 -> $5

2025-06-21

Reason

RBC Capital

Gregory Renza

Price Target

$8 -> $5

2025-06-21

downgrade

Outperform

Reason

RBC Capital analyst Gregory Renza lowered the firm's price target on ADC Therapeutics to $5 from $8 but keeps an Outperform rating on the shares. The firm says the company's high efficacy for Zynlonta in DLBCL gives it confidence in its likelihood to show clinically meaningful benefits in the 2nd line LOTIS-5 study, unlocking an additional $200M+ U.S. sales opportunity, the analyst tells investors in a research note. RBC adds that ADC shares are undervalued on the balance of a largely de-risked asset with multiple expansion opportunities that can reaccelerate growth.

Guggenheim

Buy

maintain

$7 -> $10

2025-06-13

Reason

Guggenheim

Price Target

$7 -> $10

2025-06-13

maintain

Buy

Reason

Guggenheim raised the firm's price target on ADC Therapeutics to $10 from $7 and keeps a Buy rating on the shares after the company released an update on their Phase 1b LOTIS-7 study of Zynlonta plus glofitamab as part of the EHA embargo lift. ADC also announced a $100M private placement financing intended to support Zynlonta's ongoing clinical programs and commercialization in earlier line DLBCL, as well as a restructuring comprising a 30% reduction in force and closure of UK operations, notes the analyst, who is updating the firm's estimates for all of these events.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

2025-03-31

Reason

HC Wainwright & Co.

Robert Burns

Price Target

2025-03-31

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Maintains

$10 → $7

2025-03-31

Reason

Guggenheim

Michael Schmidt

Price Target

$10 → $7

2025-03-31

Maintains

Strong Buy

Reason

Guggenheim lowered the firm's price target on ADC Therapeutics to $7 from $10 and keeps a Buy rating on the shares. Q4 results were largely consistent with prior disclosures, though Zynlonta sales of $16.4M came in below Street consensus, the analyst tells investors. The firm is updating its model to reflect a slightly more conservative timeline for potential Zynlonta label expansion into second-line Diffuse Large B-Cell Lymphoma as well as Q4 financial results.

Cantor Fitzgerald

Eric Schmidt

Buy

Reiterates

n/a

2025-03-07

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

n/a

2025-03-07

Reiterates

Buy

Reason

Stephens & Co.

Sudan Loganathan

Buy

Maintains

$6 → $8

2025-02-24

Reason

Stephens & Co.

Sudan Loganathan

Price Target

$6 → $8

2025-02-24

Maintains

Buy

Reason

Stephens raised the firm's price target on ADC Therapeutics to $8 from $6 and keeps an Overweight rating on the shares. With data from LOTIS-5 and LOTIS-7 using Zylonta as a backbone therapy in combination for second-line diffuse large B-cell lymphoma, the firm views the second-line opportunity as becoming derisked, making the stock "highly underappreciated at these levels," the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for ADC Therapeutics SA (ADCT.N) is -1.95, compared to its 5-year average forward P/E of -4.13. For a more detailed relative valuation and DCF analysis to assess ADC Therapeutics SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.13

Current PE

-1.95

Overvalued PE

-0.27

Undervalued PE

-7.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.36

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.70

Undervalued EV/EBITDA

-8.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

285.19

Current PS

4.88

Overvalued PS

1690.34

Undervalued PS

-1119.97